Advanced ovarian cancer remains a disease with a poor prognosis. Surgical therapy remains the cornerstone of treatment with essential contribution from chemotherapy. The combination therapy continues to offer the best treatment strategy. Complete cytoreductive surgery is still the most important prognostic marker. The role of primary debulking surgery in advanced ovarian cancer remains under investigation through high quality rigorous clinical trials. The current evidence regarding primary versus interval debulking surgery has drawn much criticism regarding patient recruitment and quality of surgery, both of which are key pillars in achieving complete cytoreduction. It is expected that greater centralisation and development of ‘ovarian cancer surgery teams’ will further enhance clinical outcomes.
Part of the book: Ovarian Cancer